This report was recently updated on November 15 2024 with the latest and most recent
market numbers
Global Virus-Like Particle Vaccine Market Size, Trends & Analysis - Forecasts to 2028 By Stage (Pre-clinical Research Stage and Approved Vaccines), By Distribution Channel (Healthcare Providers, Retail Pharmacies, and Government Vaccination Programs), By Application Type (Infectious Diseases, Cancer Immunotherapy, and Others), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global virus-like particle vaccine market is expected to exhibit a CAGR of 7.8% from 2023 to 2028. Vaccines that resemble the structure of viruses without including infectious genetic material are called virus-like particle (VLP) vaccines. They are a safe and effective way to stimulate an immune response against specific pathogens, such as viruses. The outside structure of a virus is closely modelled in VLP vaccinations. The proteins constituting the virus's outer coat often make up these particles. These proteins self-assemble into particles that look like actual viruses. Unlike live attenuated or inactivated vaccines, VLP vaccines do not contain any genetic material from the virus they mimic. This means they cannot replicate or cause disease in the vaccinated individual. Some examples of VLP vaccines are Gardasil, Cervarix, Energix-B, Recombivax HB, and Quadrivalent and Nonavalent Influenza Vaccines, which protect against HPV, hepatitis B, and flu strains, preventing cervical cancer.
Several factors impact the global virus-like particle vaccine market growth and evolution. Increasing awareness of the importance of vaccination for preventing infectious diseases has led to a growing demand for vaccines. VLP vaccines, with their safety and efficacy profiles, are sought-after options for various diseases. VLP vaccinations are renowned for their safety because they do not include live viruses or genetic material that might spread illness. Due to this, immunization programs frequently choose to use them, especially for vulnerable groups like children and older adults. Advances in biotechnology, particularly in genetic engineering and protein expression technologies, have made it easier and more cost-effective to produce VLPs.
The market faces several challenges that can impact its growth. Producing VLP vaccines can be technically challenging and time-consuming. The need for genetic engineering, protein expression, and purification processes can make development more complex compared to some traditional vaccine types. The production of VLP vaccines often involves sophisticated biotechnology processes, which can be expensive. These costs can make VLP vaccines less accessible, especially in low-income regions.
On the basis of stage, the market is segmented into pre-clinical research stage and approved vaccines. The approved vaccines segment is expected to be the largest segment during the forecast period as these vaccines have successfully undergone rigorous clinical trials, received regulatory approvals, and established a proven track record for safety and efficacy. Healthcare providers and governments prioritize approved vaccines due to their established effectiveness in preventing diseases, ensuring widespread adoption. This segment's dominance is also a result of public trust in well-established vaccines, making them a cornerstone of immunization programs worldwide.
On the basis of distribution channel, the market is segmented into healthcare providers, retail pharmacies, and government vaccination programs. The healthcare provider segment is expected to be the largest segment during the forecast period. This is due to its pivotal role in delivering medical services and patient care. Hospitals, outpatient centres, doctors, and other healthcare providers that provide various services are included in this sector. Several variables, including population growth and rising healthcare demands, influence the segment's growth. Additionally, advancements in medical technology and treatments have expanded the scope of healthcare services, further driving demand for healthcare providers.
The government vaccination programs segment in the global virus-like particle vaccine market is expected to be the fastest-growing segment. Governments worldwide recognize the importance of vaccination in disease prevention and have implemented robust programs to ensure widespread access. Additionally, new infectious diseases, like COVID-19, has spurred government-led vaccination drives, creating a surge in demand. These factors, along with regulatory support and procurement efforts, have accelerated the growth of government-led vaccination programs, making it the fastest-growing segment in the VLP vaccine market.
On the basis of application type, the market is segmented into infectious diseases, cancer immunotherapy, and others. The infectious diseases segment is expected to be the largest segment during the forecast period. VLP vaccines have demonstrated efficacy and safety in preventing diseases such as HPV, hepatitis B, and influenza, making them crucial tools in public health. Additionally, the ongoing threat of emerging infectious diseases and the need for effective vaccination campaigns have further boosted the prominence of VLP vaccines in this segment.
The cancer immunotherapy segment is anticipated to be the fastest-growing segment in the global virus-like particle vaccine market. VLP vaccines, like those targeting specific strains of human papillomavirus (HPV), are highly effective in preventing cancers such as cervical cancer. Growing awareness of the link between viral infections and cancer, along with government vaccination programs, has driven demand for VLP cancer vaccines, contributing to this segment's significant market share.
North America is analysed to account for the largest share of the global virus-like particle vaccine market during the forecast period. The region has a strong medical system and high healthcare spending, which facilitate vaccine research, uptake, and distribution. Also, robust research and development capabilities in the United States and Canada enable the development of innovative VLP vaccines. The solid regulatory frameworks in the U.S. ensure the safety and efficacy of vaccines, boosting public confidence. Moreover, North America's high level of disease awareness, government support, and insurance coverage promote vaccination. Lastly, the presence of major pharmaceutical companies specializing in vaccine production further propels the growth of the VLP vaccine market in the region.
Asia Pacific is expected to be the fastest growing region across the global virus-like particle vaccine market. Firstly, the region's large and densely populated countries, like China and India, create a substantial demand for vaccines to combat infectious diseases. Secondly, governments in APAC nations have increasingly prioritized public health and vaccination programs, providing funding and regulatory support. Additionally, the presence of prominent pharmaceutical and biotech companies in the region, combined with a skilled workforce, has facilitated VLP vaccine development. These factors, along with rising healthcare awareness, contribute to the rapid expansion of the VLP vaccine market in the APAC region.
Key players operating in the global virus-like particle vaccine market include Novavax, GlaxoSmithKline, Merck & Co., Medicago, Dynavax Technologies, Cytos Biotechnology, iBio, Sanofi Pasteur, Bavarian Nordic, and GeoVax Labs, among others.
Please note: This is not an exhaustive list of companies profiled in the report.
In May 2023, Icosavax, Inc., a biopharmaceutical company, announced positive results from its Phase 1 clinical trial of IVX-A12, a vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults. The company is leveraging its innovative virus-like particle (VLP) platform technology to develop pan-respiratory vaccines.
In October 2023, GeoVax Labs, a biotechnology company, has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application titled "Multivalent HIV Vaccine Boost Compositions and Methods of Use." The application covers priming vaccination with a DNA vector encoding multiple HIV antigens in virus-like particles, followed by a boost vaccination.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL VIRUS-LIKE PARTICLE VACCINE MARKET, BY APPLICATION TYPE
4.1 Introduction
4.2 Virus-Like Particle Vaccine Market: Application Type Scope Key Takeaways
4.3 Revenue Growth Analysis, 2022 & 2028
4.4 Infectious Diseases
4.4.1 Infectious Diseases Market Estimates and Forecast, 2020-2028 (USD Billion)
4.5 Cancer Immunotherapy
4.5.1 Cancer Immunotherapy Market Estimates and Forecast, 2020-2028 (USD Billion)
4.6 Others
4.6.1 Others Market Estimates and Forecast, 2020-2028 (USD Billion)
5 GLOBAL VIRUS-LIKE PARTICLE VACCINE MARKET, BY STAGE
5.1 Introduction
5.2 Virus-Like Particle Vaccine Market: Stage Scope Key Takeaways
5.3 Revenue Growth Analysis, 2022 & 2028
5.4 Pre-clinical Research Stage
5.4.1 Pre-clinical Research Stage Market Estimates and Forecast, 2020-2028 (USD Billion)
5.5 Approved Vaccines
5.5.1 Approved Vaccines Market Estimates and Forecast, 2020-2028 (USD Billion)
6 GLOBAL VIRUS-LIKE PARTICLE VACCINE MARKET, BY DISTRIBUTION CHANNEL
6.1 Introduction
6.2 Virus-Like Particle Vaccine Market: Distribution Channel Scope Key Takeaways
6.3 Revenue Growth Analysis, 2022 & 2028
6.4 Healthcare Providers
6.4.1 Healthcare Providers Market Estimates and Forecast, 2020-2028 (USD Billion)
6.5 Government Vaccination Programs
6.5.1 Government Vaccination Programs Market Estimates and Forecast, 2020-2028 (USD Billion)
6.6 Retail Pharmacies
6.6.1 Retail Pharmacies Market Estimates and Forecast, 2020-2028 (USD Billion)
7 GLOBAL VIRUS-LIKE PARTICLE VACCINE MARKET, BY REGION
7.1 Introduction
7.2 North America Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.1 By Application Type
7.2.2 By Stage
7.2.3 By Distribution Channel
7.2.4 By Country
7.2.4.1 U.S. Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.4.1.1 By Application Type
7.2.4.1.2 By Stage
7.2.4.1.3 By Distribution Channel
7.2.4.2 Canada Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.4.2.1 By Application Type
7.2.4.2.2 By Stage
7.2.4.2.3 By Distribution Channel
7.2.4.3 Mexico Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.2.4.3.1 By Application Type
7.2.4.3.2 By Stage
7.2.4.3.3 By Distribution Channel
7.3 Europe Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.1 By Application Type
7.3.2 By Stage
7.3.3 By Distribution Channel
7.3.4 By Country
7.3.4.1 Germany Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.1.1 By Application Type
7.3.4.1.2 By Stage
7.3.4.1.3 By Distribution Channel
7.3.4.2 U.K. Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.2.1 By Application Type
7.3.4.2.2 By Stage
7.3.4.2.3 By Distribution Channel
7.3.4.3 France Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.3.1 By Application Type
7.3.4.3.2 By Stage
7.3.4.3.3 By Distribution Channel
7.3.4.4 Italy Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.4.1 By Application Type
7.3.4.4.2 By Stage
7.2.4.4.3 By Distribution Channel
7.3.4.5 Spain Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.5.1 By Application Type
7.3.4.5.2 By Stage
7.2.4.5.3 By Distribution Channel
7.3.4.6 Netherlands Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.7.1 By Application Type
7.3.4.7.2 By Stage
7.2.4.7.3 By Distribution Channel
7.3.4.7 Rest of Europe Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.3.4.7.1 By Application Type
7.3.4.7.2 By Stage
7.2.4.7.3 By Distribution Channel
7.4 Asia Pacific Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.1 By Application Type
7.4.2 By Stage
7.4.3 By Distribution Channel
7.4.4 By Country
7.4.4.1 China Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.1.1 By Application Type
7.4.4.1.2 By Stage
7.4.4.1.3 By Distribution Channel
7.4.4.2 Japan Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.2.1 By Application Type
7.4.4.2.2 By Stage
7.4.4.2.3 By Distribution Channel
7.4.4.3 India Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.3.1 By Application Type
7.4.4.3.2 By Stage
7.4.4.3.3 By Distribution Channel
7.4.4.4 South Korea Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.4.1 By Application Type
7.4.4.4.2 By Stage
7.4.4.4.3 By Distribution Channel
7.4.4.5 Singapore Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.5.1 By Application Type
7.4.4.5.2 By Stage
7.4.4.5.3 By Distribution Channel
7.4.4.6 Malaysia Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.7.1 By Application Type
7.4.4.7.2 By Stage
7.4.4.7.3 By Distribution Channel
7.4.4.7 Thailand Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.7.1 By Application Type
7.4.4.7.2 By Stage
7.4.4.7.3 By Distribution Channel
7.4.4.8 Indonesia Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.8.1 By Application Type
7.4.4.8.2 By Stage
7.4.4.8.3 By Distribution Channel
7.4.4.9 Vietnam Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.9.1 By Application Type
7.4.4.9.2 By Stage
7.4.4.9.3 By Distribution Channel
7.4.4.10 Taiwan Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.10.1 By Application Type
7.4.4.10.2 By Stage
7.4.4.10.3 By Distribution Channel
7.4.4.11 Rest of Asia Pacific Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.4.4.11.1 By Application Type
7.4.4.11.2 By Stage
7.4.4.11.3 By Distribution Channel
7.5 Middle East and Africa Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.1 By Application Type
7.5.2 By Stage
7.5.3 By Distribution Channel
7.5.4 By Country
7.5.4.1 Saudi Arabia Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.1.1 By Application Type
7.5.4.1.2 By Stage
7.5.4.1.3 By Distribution Channel
7.5.4.2 U.A.E. Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.2.1 By Application Type
7.5.4.2.2 By Stage
7.5.4.2.3 By Distribution Channel
7.5.4.3 Israel Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.3.1 By Application Type
7.5.4.3.2 By Stage
7.5.4.3.3 By Distribution Channel
7.5.4.4 South Africa Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.4.1 By Application Type
7.5.4.4.2 By Stage
7.5.4.4.3 By Distribution Channel
7.5.4.5 Rest of Middle East and Africa Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.5.4.5.1 By Application Type
7.5.4.5.2 By Stage
7.5.4.5.2 By Distribution Channel
7.6 Central and South America Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.1 By Application Type
7.7.2 By Stage
7.7.3 By Distribution Channel
7.7.4 By Country
7.7.4.1 Brazil Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.1.1 By Application Type
7.7.4.1.2 By Stage
7.7.4.1.3 By Distribution Channel
7.7.4.2 Argentina Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.2.1 By Application Type
7.7.4.2.2 By Stage
7.7.4.2.3 By Distribution Channel
7.7.4.3 Chile Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.3.1 By Application Type
7.7.4.3.2 By Stage
7.7.4.3.3 By Distribution Channel
7.7.4.4 Rest of Central and South America Virus-Like Particle Vaccine Market Estimates and Forecast, 2020-2028 (USD Billion)
7.7.4.4.1 By Application Type
7.7.4.4.2 By Stage
7.7.4.4.3 By Distribution Channel
8 COMPETITIVE LANDCAPE
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.2.1 Market Leaders
8.2.2 Market Visionaries
8.2.3 Market Challengers
8.2.4 Niche Market Players
8.3 Vendor Landscape
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Rest of the World
8.4 Company Profiles
8.4.1 Novavax
8.4.1.1 Business Description & Financial Analysis
8.4.1.2 SWOT Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2 GlaxoSmithKline (GSK)
8.4.2.1 Business Description & Financial Analysis
8.4.2.2 SWOT Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 Merck & Co.
8.4.3.1 Business Description & Financial Analysis
8.4.3.2 SWOT Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4 Medicago
8.4.4.1 Business Description & Financial Analysis
8.4.4.2 SWOT Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Dynavax Technologies
8.4.5.1 Business Description & Financial Analysis
8.4.5.2 SWOT Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.6 Cytos Biotechnology
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.7.4 Strategic Alliances between Business Partners
8.4.7 IBio
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8 Sanofi Pasteur
8.4.8.1 Business Description & Financial Analysis
8.4.8.2 SWOT Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 Bavarian Nordic
8.4.9.1 Business Description & Financial Analysis
8.4.9.2 SWOT Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10 Other Companies
8.4.10.1 Business Description & Financial Analysis
8.4.10.2 SWOT Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
9 RESEARCH METHODOLOGY
9.1 Market Introduction
9.1.1 Market Definition
9.1.2 Market Scope & Segmentation
9.2 Information Procurement
9.2.1 Secondary Research
9.2.1.1 Purchased Databases
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2 Primary Research
9.2.2.1 Various Types of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.3 Primary Stakeholders
9.2.2.4 Discussion Guide for Primary Participants
9.2.3 Expert Panels
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4 Paid Local Experts
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3 Market Estimation
9.3.1 Top-Down Approach
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2 Bottom Up Approach
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Product Sales
9.4 Data Triangulation
9.4.1 Data Collection
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.4.3 Cluster Analysis
9.5 Analysis and Output
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
9.7.1 Research Assumptions
9.7.2 Research Limitations
LIST OF TABLES
1 Global Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
2 Infectious Diseases Market, By Region, 2020-2028 (USD Billion)
3 Cancer Immunotherapy Market, By Region, 2020-2028 (USD Billion)
4 Others Market, By Region, 2020-2028 (USD Billion)
5 Global Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
6 PRE-CLINICAL RESEARCH STAGE Market, By Region, 2020-2028 (USD Billion)
7 APPROVED VACCINES Market, By Region, 2020-2028 (USD Billion)
8 Global Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
9 Healthcare Providers Market, By Region, 2020-2028 (USD Billion)
10 Government Vaccination Programs Market, By Region, 2020-2028 (USD Billion)
11 Retail Pharmacies Market, By Region, 2020-2028 (USD Billion)
12 Regional Analysis, 2020-2028 (USD Billion)
13 North America Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
14 North America Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
15 North America Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
16 North America Virus-Like Particle Vaccine Market, By Country, 2020-2028 (USD Billion)
17 U.S. Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
18 U.S. Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
19 U.S Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
20 Canada Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
21 Canada Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
22 Canada Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
23 Mexico Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
24 Mexico Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
25 Mexico Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
26 Europe Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
27 Europe Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
28 Europe Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
29 Germany Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
30 Germany Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
31 Germany Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
32 U.K. Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
33 U.K. Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
34 U.K. Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
35 France Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
36 France Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
37 France Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
38 Italy Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
39 Italy Virus-Like Particle Vaccine Market, By T Stage Type, 2020-2028 (USD Billion)
40 Italy Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
41 Spain Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
42 Spain Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
43 Spain Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
44 Rest Of Europe Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
45 Rest Of Europe Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
46 Rest of Europe Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
47 Asia Pacific Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
48 Asia Pacific Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
49 Asia Pacific Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
50 Asia Pacific Virus-Like Particle Vaccine Market, By Country, 2020-2028 (USD Billion)
51 China Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
52 China Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
53 China Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
54 India Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
55 India Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
56 India Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
57 Japan Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
58 Japan Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
59 Japan Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
60 South Korea Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
61 South Korea Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
62 South Korea Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
63 Middle East and Africa Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
64 Middle East and Africa Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
65 Middle East and Africa Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
66 Middle East and Africa Virus-Like Particle Vaccine Market, By Country, 2020-2028 (USD Billion)
67 Saudi Arabia Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
68 Saudi Arabia Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
69 Saudi Arabia Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
70 UAE Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
71 UAE Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
72 UAE Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
73 Central and South America Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
74 Central and South America Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
75 Central and South America Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
76 Central and South America Virus-Like Particle Vaccine Market, By Country, 2020-2028 (USD Billion)
77 Brazil Virus-Like Particle Vaccine Market, By Application Type, 2020-2028 (USD Billion)
78 Brazil Virus-Like Particle Vaccine Market, By Stage, 2020-2028 (USD Billion)
79 Brazil Virus-Like Particle Vaccine Market, By Distribution Channel, 2020-2028 (USD Billion)
80 Novavax: Products & Services Offering
81 GlaxoSmithKline (GSK): Products & Services Offering
82 Merck & Co.: Products & Services Offering
83 Medicago: Products & Services Offering
84 Dynavax Technologies: Products & Services Offering
85 CYTOS BIOTECHNOLOGY: Products & Services Offering
86 IBio : Products & Services Offering
87 Sanofi Pasteur: Products & Services Offering
88 BAVARIAN NORDIC, Inc: Products & Services Offering
89 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Virus-Like Particle Vaccine Market Overview
2 Global Virus-Like Particle Vaccine Market Value From 2020-2028 (USD Billion)
3 Global Virus-Like Particle Vaccine Market Share, By Application Type (2022)
4 Global Virus-Like Particle Vaccine Market Share, By Stage (2022)
5 Global Virus-Like Particle Vaccine Market Share, By Distribution Channel (2022)
6 Global Virus-Like Particle Vaccine Market, By Region (Asia Pacific Market)
7 Technological Trends In Global Virus-Like Particle Vaccine Market
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global Virus-Like Particle Vaccine Market
11 Impact Of Challenges On The Global Virus-Like Particle Vaccine Market
12 Porter’s Five Forces Analysis
13 Global Virus-Like Particle Vaccine Market: By Application Type Scope Key Takeaways
14 Global Virus-Like Particle Vaccine Market, By Application Type Segment: Revenue Growth Analysis
15 Infectious Diseases Market, By Region, 2020-2028 (USD Billion)
16 Cancer Immunotherapy Market, By Region, 2020-2028 (USD Billion)
17 Others Market, By Region, 2020-2028 (USD Billion)
18 Global Virus-Like Particle Vaccine Market: By Stage Scope Key Takeaways
19 Global Virus-Like Particle Vaccine Market, By Stage Segment: Revenue Growth Analysis
20 Pre-clinical Research Stage Market, By Region, 2020-2028 (USD Billion)
21 Approved Vaccines Market, By Region, 2020-2028 (USD Billion)
22 Global Virus-Like Particle Vaccine Market: By Distribution Channel Scope Key Takeaways
23 Global Virus-Like Particle Vaccine Market, By Distribution Channel Segment: Revenue Growth Analysis
24 Healthcare Providers Market, By Region, 2020-2028 (USD Billion)
25 Government Vaccination Programs Market, By Region, 2020-2028 (USD Billion)
26 Retail Pharmacies Market, By Region, 2020-2028 (USD Billion)
27 Regional Segment: Revenue Growth Analysis
28 Global Virus-Like Particle Vaccine Market: Regional Analysis
29 North America Virus-Like Particle Vaccine Market Overview
30 North America Virus-Like Particle Vaccine Market, By Application Type
31 North America Virus-Like Particle Vaccine Market, By Stage
32 North America Virus-Like Particle Vaccine Market, By Distribution Channel
33 North America Virus-Like Particle Vaccine Market, By Country
34 U.S. Virus-Like Particle Vaccine Market, By Application Type
35 U.S. Virus-Like Particle Vaccine Market, By Stage
36 U.S. Virus-Like Particle Vaccine Market, By Distribution Channel
37 Canada Virus-Like Particle Vaccine Market, By Application Type
38 Canada Virus-Like Particle Vaccine Market, By Stage
39 Canada Virus-Like Particle Vaccine Market, By Distribution Channel
40 Mexico Virus-Like Particle Vaccine Market, By Application Type
41 Mexico Virus-Like Particle Vaccine Market, By Stage
42 Mexico Virus-Like Particle Vaccine Market, By Distribution Channel
43 Four Quadrant Positioning Matrix
44 Company Market Share Analysis
45 Novavax: Company Snapshot
46 Novavax: SWOT Analysis
47 Novavax: Geographic Presence
48 GlaxoSmithKline (GSK): Company Snapshot
49 GlaxoSmithKline (GSK): SWOT Analysis
50 GlaxoSmithKline (GSK): Geographic Presence
51 Merck & Co.: Company Snapshot
52 Merck & Co.: SWOT Analysis
53 Merck & Co.: Geographic Presence
54 Medicago: Company Snapshot
55 Medicago: Swot Analysis
56 Medicago: Geographic Presence
57 Dynavax Technologies: Company Snapshot
58 Dynavax Technologies: SWOT Analysis
59 Dynavax Technologies: Geographic Presence
60 Cytos Biotechnology: Company Snapshot
61 Cytos Biotechnology: SWOT Analysis
62 Cytos Biotechnology: Geographic Presence
63 IBio : Company Snapshot
64 IBio : SWOT Analysis
65 IBio : Geographic Presence
66 Sanofi Pasteur: Company Snapshot
67 Sanofi Pasteur: SWOT Analysis
68 Sanofi Pasteur: Geographic Presence
69 Bavarian Nordic, Inc.: Company Snapshot
70 Bavarian Nordic, Inc.: SWOT Analysis
71 Bavarian Nordic, Inc.: Geographic Presence
72 Other Companies: Company Snapshot
73 Other Companies: SWOT Analysis
74 Other Companies: Geographic Presence
The Global Virus-Like Particle Vaccine Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Virus-Like Particle Vaccine Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
